Theralase Technologies Inc (TLTFF)

[was CUIN2]

Mr. Dumoulin-White went on to say, "Our patented anti-cancer technology has demonstrated significant success in preclinical research and is on track for completion of preclinical evaluation in late 2014 / early 2015. Theralase is anticipating enrollment of patients into a Phase I / II a clinical trial for bladder cancer in 2015, pending Health Canada and the United States Food and Drug Administration ("FDA") of a Clinical Trial Application ("CTA") and Investigational New Drug ("IND") application, respectively. If our PDC technology, with its recent advances, that have been validated three times, provides an immune-mediated "memory response" in the destruction and prevention of cancer in human cancer patients, the implications of this discovery would be immense for Theralase and more importantly for the cancer patients who are inflicted with this deadly disease. The ability to destroy the primary tumour and program the immune system to prevent micro metastasis to prevent recurrence, after a single treatment, is startling. Theralase is fully dedicated to commercializing this anti-cancer PDC technology in the shortest possible time in order to help heal cancer patients, who need our help the most."

http://finance.yahoo.com/news/theralase-releases-3q2014-financials-133500251.html;_ylt=AwrBEiQa.JBUHB4AAyOZmolQ